References
- Olsson AG, McTaggart F, Raza A. Rosuvastatin: a highly effective new HMG‑CoA reductase inhibitor. Cardiovasc Drug Rev 2002;20:303–28
- Martin PD, Warwick MJ, Dane AL, Cantarini MV. A doubleblind, randomized, incomplete crossover trial to assess the dose proportionality of rosuvastatin in healthy volunteers. Clin Ther 2003;25:2215–24
- Cooper KJ, Martin PD, Dane AL, et al. The effect of fluconazole on the pharmacokinetics of rosuvastatin. Eur J Clin Pharmacol 2002;58:527–31
- Cooper KJ, Martin PD, Dane AL, et al. Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthysubjects. Br J Clin Pharmacol 2003;55:94–9
- Cooper KJ, Martin PD, Dane AL, et al. Effect of itraconazole on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther 2003;73:322–9
- Cooper KJ, Martin PD, Dane AL, et al. The effect of erythromycin on the pharmacokinetics of rosuvastatin. Eur J Clin Pharmacol 2003;59:51–6
- Martin PD, Dane AL, Nwose OM, et al. No effect of age or gender on the pharmacokinetics of rosuvastatin: a new HMG-CoA reductase inhibitor. J Clin Pharmacol 2002;42:1116–21
- Martin PD, Mitchell PD, Schneck DW. Pharmacodynamic effects and pharmacokinetics of a new HMG‑CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers. Br J Clin Pharmacol 2002;54:472–7
- Martin PD, Warwick MJ, Dane AL, et al. Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers. Clin Ther 2003;25:2553–63
- Martin PD, Warwick MJ, Dane AL, et al. Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers. Clin Ther 2003;25:2822–35
- Shitara Y, Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug–drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther 2006;112:71–105
- Maton PN, Burton ME. Antacids revisited: a review of their clinical pharmacology and recommended therapeutic use. Drugs 1999;57:855–70
- Sadowski DC. Drug interactions with antacids. Mechanisms and clinical significance. Drug Saf 1994;11:395–407
- Flockhart DA, Desta Z, Mahal SK. Selection of drugs to treat gastro-oesophageal reflux disease: the role of drug interactions. Clin Pharmacokinet 2000;39:295–309
- Hull CK, Penman AD, Smith CK, Martin PD. Quantification of rosuvastatin in human plasma by automated solid-phase extraction using tandem mass spectrometric detection. J Chromatogr B Analyt Technol Biomed Life Sci 2002;772: 219–28
- Tucker GT, Houston JB, Huang S-M. Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential – towards a consensus. Clin Pharmacol Ther 2001;70:103–114
- Yang B-B, Smithers JA, Abel RB, et al. Effects of Maalox TCR on pharmacokinetics and pharmacodynamics of atorvastatin. Pharm Res 1996;13:S-437 (abstract PPDM 8178)
- Muck W, Ritter W, Dietrich H, et al. Influence of the antacid Maalox and the H2-antagonist cimetidine on the pharmacokinetics of cerivastatin. Int J Clin Pharmacol Ther 1997;35:261–4
- Stern RH, Gibson DM, Whitfield LR. Cimetidine does not alter atorvastatin pharmacokinetics or LDL-cholesterol reduction. Eur J Clin Pharmacol 1998;53:475–8
- McKenney JM. Efficacy and safety of rosuvastatin in treatment of dyslipidemia. Am J Health Syst Pharm 2005;62:1033–47